Drug Trial Radar · NCT00379769
RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes
Last checked: Nov 19, 2026Latest source record: Mar 23, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,447
Actual
Start
Apr 2001
Primary completion
Dec 2008
Study completion Dec 2008
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Sep 22, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a phase 3b, multicentre, randomised, open label, parallel group study. A 4-week run-in period will be followed by a median of 6 years of treatment with study medication in addition to continuation of background glucose lowering therapy. Patients inadequately controlled on background metformin will be randomised to receive, in addition to metformin, either rosiglitazone or a sulfonylurea(glibenclamide, gliclazide or glimepiride) in a ratio of 1:1. Patients inadequately controlled on background SU will be randomised to receive, in addition to SU, either rosiglitazone or metformin in a ratio of 1:1. Equal numbers of patients receiving background metformin and SU at entry will be entered into the study.
Conditions
- Diabetes Mellitus, Type 2
Interventions
RosiglitazoneDrug
Rosiglitazone maximum 8 mg per day
SulfonylureaDrug
Sulfonylurea (SU) maximum permitted daily dose
MetforminDrug
Metformin maximum permitted daily dose .
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Cardiovascular Death/Cardiovascular Hospitalisation EventsTime frame: Baseline through End of Study (up to 7.5 years)
- Independent Re-adjudication Outcome: Number of Participants Who Died Due to Any CauseTime frame: Baseline through End of Study (up to 7.5 years)
- Independent Re-adjudication (IR) Outcome: Number of Participants With a First Occurrence of a Major Adverse Cardiovascular Event (MACE) Defined as CV (or Unknown) Death, Non-fatal MI, and Non-fatal Stroke Based on Original RECORD Endpoint DefinitionsTime frame: Baseline through End of Study (up to 7.5 years)
- Independent Re-adjudication Outcome: Number of Participants With a First Occurrence of a Major Adverse Cardiovascular Event (MACE) Defined as CV (or Unknown) Death, Non-fatal MI, and Non-fatal Stroke Based on Contemporary Endpoint DefinitionsTime frame: Baseline through End of Study (up to 7.5 years)
- Independent Re-adjudication Outcome: Number of Participants With a CV (or Unknown) Death, Based on Original RECORD Endpoint DefinitionsTime frame: Baseline through End of Study (up to 7.5 years)
- Independent Re-adjudication Outcome: Number of Participants With a CV (or Unknown) Death, Based on Contemporary Endpoint DefinitionsTime frame: Baseline through End of Study (up to 7.5 years)
- Independent Re-adjudication Outcome: Number of Participants With an Event of Myocardial Infarction (Fatal and Non-fatal), Based on Original RECORD Endpoint DefinitionsTime frame: Baseline through End of Study (up to 7.5 years)
- Independent Re-adjudication Outcome: Number of Participants With an Event of Myocardial Infarction (Fatal and Non-fatal), Based on Contemporary Endpoint DefinitionsTime frame: Baseline through End of Study (up to 7.5 years)
- Independent Re-adjudication Outcome: Number of Participants (Par.) With an Event of Stroke (Fatal and Non-fatal), Based on Original RECORD Endpoint DefinitionsTime frame: Baseline through End of Study (up to 7.5 years)
- Independent Re-adjudication Outcome: Number of Participants With an Event of Stroke (Fatal and Non-fatal), Based on Contemporary Endpoint DefinitionsTime frame: Baseline through End of Study (up to 7.5 years)
Locations
446 sites in 25 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Miranda, New South Wales, Australia
GSK Investigational Site
Randwick, New South Wales, Australia
GSK Investigational Site
Wollongong, New South Wales, Australia
GSK Investigational Site
Carina Heights, Queensland, Australia
GSK Investigational Site
Kippa-Ring, Queensland, Australia
GSK Investigational Site
Sherwood, Queensland, Australia
GSK Investigational Site
Keswick, South Australia, Australia
GSK Investigational Site
North Adelaide, South Australia, Australia
GSK Investigational Site
Port Lincoln, South Australia, Australia
GSK Investigational Site
Heidelberg, Victoria, Australia
GSK Investigational Site
Malvern, Victoria, Australia
GSK Investigational Site
Antwerp, Belgium
GSK Investigational Site
Arlon, Belgium
GSK Investigational Site
Brussels, Belgium
GSK Investigational Site
Edegem, Belgium
GSK Investigational Site
Genk, Belgium
GSK Investigational Site
Ghent, Belgium
GSK Investigational Site
Kortrijk, Belgium
GSK Investigational Site
Liège, Belgium
GSK Investigational Site
Moerkerke, Belgium
GSK Investigational Site
Oostham, Belgium
GSK Investigational Site
Roeselare, Belgium
GSK Investigational Site
Sint-Gillis-Waas, Belgium
GSK Investigational Site
Vilvoorde, Belgium
GSK Investigational Site
Pleven, Bulgaria
GSK Investigational Site
Plovdiv, Bulgaria
GSK Investigational Site
Sofia, Bulgaria
GSK Investigational Site
Sofia, Bulgaria
GSK Investigational Site
Sofia, Bulgaria
GSK Investigational Site
Sofia, Bulgaria
GSK Investigational Site
Sofia, Bulgaria
GSK Investigational Site
Varna, Bulgaria
GSK Investigational Site
Krapinske Toplice, Croatia
GSK Investigational Site
Rijeka, Croatia
GSK Investigational Site
Slavonski Brod, Croatia
GSK Investigational Site
Varaždin, Croatia
GSK Investigational Site
Zagreb, Croatia
GSK Investigational Site
Brno, Czechia
GSK Investigational Site
České Budějovice, Czechia
GSK Investigational Site
Holice V Cechach, Czechia
Showing 40 of 446 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.